143 related articles for article (PubMed ID: 30975390)
1. Conditional Financing of Drugs in the Netherlands: Past, Present, and Future-Results From Stakeholder Interviews.
Makady A; van Acker S; Nijmeijer H; de Boer A; Hillege H; Klungel O; Goettsch W
Value Health; 2019 Apr; 22(4):399-407. PubMed ID: 30975390
[TBL] [Abstract][Full Text] [Related]
2. Implementing managed entry agreements in practice: The Dutch reality check.
Makady A; van Veelen A; de Boer A; Hillege H; Klungel OH; Goettsch W
Health Policy; 2019 Mar; 123(3):267-274. PubMed ID: 30316540
[TBL] [Abstract][Full Text] [Related]
3. Factors influencing access to kidney transplantation: a research protocol of a qualitative study on stakeholders' perspectives.
Kloss K; Ismail S; Redeker S; van Hoogdalem L; Luchtenburg A; Busschbach JJV; van de Wetering J
BMJ Open; 2019 Sep; 9(9):e032694. PubMed ID: 31558463
[TBL] [Abstract][Full Text] [Related]
4. Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies.
Makady A; Ham RT; de Boer A; Hillege H; Klungel O; Goettsch W;
Value Health; 2017 Apr; 20(4):520-532. PubMed ID: 28407993
[TBL] [Abstract][Full Text] [Related]
5. Involving patients in health technology funding decisions: stakeholder perspectives on processes used in Australia.
Lopes E; Street J; Carter D; Merlin T
Health Expect; 2016 Apr; 19(2):331-44. PubMed ID: 25703958
[TBL] [Abstract][Full Text] [Related]
6. Value-based payment for high-cost treatments in Singapore: a qualitative study of stakeholders' perspectives.
Bayani DB; Wee HL
Int J Technol Assess Health Care; 2024 Apr; 40(1):e22. PubMed ID: 38629196
[TBL] [Abstract][Full Text] [Related]
7. Increasing the Legitimacy of Tough Choices in Healthcare Reimbursement: Approach and Results of a Citizen Forum in The Netherlands.
Bijlmakers L; Jansen M; Boer B; van Dijk W; Groenewoud S; Zwaap J; Helderman JK; van Exel J; Baltussen R
Value Health; 2020 Jan; 23(1):32-38. PubMed ID: 31952671
[TBL] [Abstract][Full Text] [Related]
8. How executives' expectations and experiences shape population health management strategies.
Steenkamer BM; Drewes HW; van Vooren N; Baan CA; van Oers H; Putters K
BMC Health Serv Res; 2019 Oct; 19(1):757. PubMed ID: 31655602
[TBL] [Abstract][Full Text] [Related]
9. Harmonization of HTA--based reimbursement and regulatory approval activities: a qualitative study.
Tsoi B; O'Reilly D; Masucci L; Drummond M; Goeree R
J Popul Ther Clin Pharmacol; 2015; 22(1):e78-89. PubMed ID: 25715384
[TBL] [Abstract][Full Text] [Related]
10. Similarities and differences between stakeholders' opinions on using Health Technology Assessment (HTA) information across five European countries: results from the EQUIPT survey.
Vokó Z; Cheung KL; Józwiak-Hagymásy J; Wolfenstetter S; Jones T; Muñoz C; Evers SM; Hiligsmann M; de Vries H; Pokhrel S;
Health Res Policy Syst; 2016 May; 14(1):38. PubMed ID: 27230485
[TBL] [Abstract][Full Text] [Related]
11. Uncertainty and Coverage With Evidence Development: Does Practice Meet Theory?
Pouwels XGLV; Grutters JPC; Bindels J; Ramaekers BLT; Joore MA
Value Health; 2019 Jul; 22(7):799-807. PubMed ID: 31277827
[TBL] [Abstract][Full Text] [Related]
12. Regulation of health-related technologies in Germany.
Perleth M; Busse R; Schwartz FW
Health Policy; 1999 Jan; 46(2):105-26. PubMed ID: 10346284
[TBL] [Abstract][Full Text] [Related]
13. Harmonization of reimbursement and regulatory approval processes: a systematic review of international experiences.
Tsoi B; Masucci L; Campbell K; Drummond M; O'Reilly D; Goeree R
Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):497-511. PubMed ID: 23977976
[TBL] [Abstract][Full Text] [Related]
14. "Stick or Twist?" Negotiating Price and Data in an Era of Conditional Approval.
Gladwell D; Bullement A; Cowell W; Patterson K; Strong M
Value Health; 2020 Feb; 23(2):191-199. PubMed ID: 32113624
[TBL] [Abstract][Full Text] [Related]
15. Preferences on policy options for ensuring the financial sustainability of health care services in the future: results of a stakeholder survey.
Tordrup D; Angelis A; Kanavos P
Appl Health Econ Health Policy; 2013 Dec; 11(6):639-52. PubMed ID: 24129648
[TBL] [Abstract][Full Text] [Related]
16. National stakeholders' perceptions of the processes that inform the development of national clinical practice guidelines for primary healthcare in South Africa.
Kredo T; Cooper S; Abrams A; Daniels K; Volmink J; Atkins S
Health Res Policy Syst; 2018 Jul; 16(1):68. PubMed ID: 30064440
[TBL] [Abstract][Full Text] [Related]
17. When Reality Does Not Meet Expectations-Experiences and Perceived Attitudes of Dutch Stakeholders Regarding Payment and Reimbursement Models for High-Priced Hospital Drugs.
Callenbach MHE; Vreman RA; Mantel-Teeuwisse AK; Goettsch WG
Int J Environ Res Public Health; 2022 Dec; 20(1):. PubMed ID: 36612665
[TBL] [Abstract][Full Text] [Related]
18. STAKEHOLDER INVOLVEMENT IN THE HEALTH TECHNOLOGY ASSESSMENT PROCESS IN LATIN AMERICA.
Pichon-Riviere A; Soto N; Augustovski F; Sampietro-Colom L
Int J Technol Assess Health Care; 2018 Jan; 34(3):248-253. PubMed ID: 29888698
[TBL] [Abstract][Full Text] [Related]
19. Financing of physical rehabilitation services in Iran: a stakeholder and social network analysis.
Shahabi S; Ahmadi Teymourlouy A; Shabaninejad H; Kamali M; Lankarani KB
BMC Health Serv Res; 2020 Jul; 20(1):599. PubMed ID: 32611339
[TBL] [Abstract][Full Text] [Related]
20. Use of real-world evidence in cancer drug funding decisions in Canada: a qualitative study of stakeholders' perspectives.
Clausen M; Mighton C; Kiflen R; Sebastian A; Dai WF; Mercer RE; Beca JM; Isaranuwatchai W; Chan KKW; Bombard Y
CMAJ Open; 2020; 8(4):E772-E778. PubMed ID: 33234584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
